OUR CUTTING-EDGE PRODUCTS

Early Detec­tion of Cancer Tests

The early detection tests are applied to indi­vid­u­als who have a high risk to develop can­cer, e.g., due to a fam­ily his­tory or genetic pre­dis­po­si­tion.

Due to their out­stand­ing diag­nos­tic pre­ci­sion, these tests have high poten­tial to be used for population-​wide screen­ing in the long ​term.

Our tests

  • enable erlier detection of pre-malignant lesions and cancer of the ovaries, fallopian tubes or the endometrium;

  • enable timely detec­tion of pri­mary and relapsed can­cer so that cura­tive mea­sures are still possible;

  • guide physi­cians select­ing the most appro­pri­ate ther­apy for each indi­vid­ual patient;

  • run on com­mer­cially avail­able analy­sis platforms.

The Immune Signature Tests are non-​invasive and are based on novel con­cepts ensur­ing unprece­dented sen­si­tiv­ity and speci­ficity. Proof-of-principle studies were performed for ovar­ian, breast and pan­cre­atic can­cer. The test prin­ci­ples allow application in other major types of cancer.

Prognosis, Prediction and Monitoring Tests

These tests allow doctors to chose the most effi­cient treat­ment for their cancer patients. In addition, the tests will be designed to detect ther­apy fail­ures and/or can­cer recur­rence at an early statge which allows re-defining and adjusting the therapy in a timely manner.

The tests will be used to assess in real time whether the current therapy is effective or not. They will be applied at dif­fer­ent time points, namely before, dur­ing and after the ther­apy. When used in follow-​up sur­veil­lance after com­ple­tion of a  ther­apy, the monitoring tests even enable early detec­tion of a possible can­cer relapse.

Due to their non-​invasive nature and easy applic­a­bil­ity these blood tests rep­re­sent so-called LIQ­UID BIOP­SIES which— unlike tis­sue biop­sies — can the­o­ret­i­cally be per­formed an unlim­ited num­ber of times.

Our tests will be pro­vided in the form of test kits that con­tain all reagents nec­es­sary to per­form the tests on a com­mer­cially avail­able analy­sis platform.

oncolab_logo_transparent_1246x281

OncoLab Diagnostics GmbH
Hebbelplatz 5
1100 Vienna
Austria

© OncoLab Diagnostics GmbH, 2017